Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia

Induction therapy for patients with acute myeloid leukemia (AML) has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies. The PI3K/Akt pathway is constitutively active in the majority of patients with AML. Given...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Li, Xinyu, Su, Yongwei, Madlambayan, Gerard, Edwards, Holly, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H., White, Kathryn, Ma, Jun, Knight, Tristan, Wang, Guan, Wang, Yue, Yang, Jay, Taub, Jeffrey W., Lin, Hai, Ge, Yubin
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821619/
https://ncbi.nlm.nih.gov/pubmed/30819918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201343
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars